Amarin (AMRN) Q4 2025 earnings review
Strategic Pivot Delivers Positive Cash Flow Ahead of Schedule
Amarin’s dramatic shift to a fully-partnered European model and aggressive global restructuring is yielding immediate results. While Q4 total net revenue fell 21% YoY to $49.2M—largely due to a tough comp against prior-year Rest of World stocking orders and the shift away from direct European sales—the real story is the bottom line. Adjusted operating expenses plunged 41% YoY, narrowing the net loss to just $1.2M. Most impressively, the company achieved a Reversing trend in cash flow, turning positive in Q4 and boosting its cash pile to $303M. With the US business remarkably resilient against generics and the cost structure rightsized, management projects sustainable positive cash flow for FY26.
🐂 Bull Case
The company achieved positive cash flow in Q4 ahead of schedule. With zero debt and $303M in the bank, the existential threat of cash burn has been neutralized, and FY26 is guided for sustainable positive cash flow.
The operational rightsizing following the Recordati agreement is working. The company has realized $31M of its $70M cost-saving target and expects the full run-rate benefit by mid-2026.
🐻 Bear Case
Total revenue declined 21% YoY. Partner-driven models mean volatile, lumpy quarter-to-quarter ex-US revenue, as seen by the 74% YoY collapse in ROW revenue due to the timing of stocking orders.
The shift to supply sales for European partners inherently lowers gross margin percentages compared to direct commercialization, increasing reliance on strict OPEX control.
⚖️ Verdict: 🔴🔴
Bullish. Management has successfully navigated a difficult transition from a cash-burning direct commercialization model to a leaner, partner-driven organization. Hitting positive cash flow early proves the viability of the new strategy.
Key Themes
OPEX Rightsizing Accelerates Profitability
Following the June 2025 licensing agreement with Recordati, Amarin drastically reduced its European commercial footprint. This restructuring resulted in a Decelerating trend in SG&A expenses, which fell 46% YoY to $20.1M in Q4. This aggressive cost containment is the primary driver behind the Reversing trend from cash burn to cash generation.
Stubborn US Market Share Defies Generic Gravity
Five years after generic entry, VASCEPA impressively maintains over 50% of the U.S. icosapent ethyl (IPE) market. While US product revenue is down 7% YoY due to net pricing pressures, it has been Stable sequentially throughout 2025. Management has strategically retained key exclusive PBM contracts, ensuring the US remains the foundational cash cow.
Scientific Validation from FDA Action
Management continues to highlight a critical macro/scientific catalyst: the FDA's recent decision to update fenofibrate labels explicitly stating a lack of cardiovascular benefit. With REDUCE-IT trial data showing a 25% MACE reduction, Amarin aims to use this regulatory validation to displace fibrate usage globally, leveraging its network of 7 partners across 100 markets.
International Revenue Volatility
A major side effect of the new partnered model is the highly erratic nature of international revenue recognition. Rest of World (ROW) revenue plunged 74% YoY to $3.1M, as Q4 2024 included a massive $7.8M launch stocking order. Furthermore, European revenue dropped 42% YoY to $2.3M because sales have transitioned from high-value direct retail to lower-value wholesale supply shipments to Recordati.
Gross Margin Dilution Inherent to New Strategy
While operating margins are vastly improved, the gross margin profile will structurally decline. Selling supply to partners like Recordati at wholesale prices yields a lower gross margin percentage than direct-to-patient sales. Gross profit fell to $23.1M from the adjusted norms of prior quarters, meaning the company must rely strictly on OPEX reductions to ensure top-line margin compression doesn't threaten the bottom line.
Dependency on Partner Execution
By shifting from a direct sales force to Recordati, Amarin is entirely dependent on a third party to drive VAZKEPA adoption across 59 countries. If Recordati fails to effectively leverage its primary care infrastructure or delays launch sequences, Amarin's royalty stream and milestone payments will stall, with limited ability for management to intervene.
Ongoing Strategic Review
The company reiterated that it is actively examining strategic actions to maximize shareholder value with exclusive financial advisor Barclays. Management noted they operate from an 'improved position of market, operational, and financial strength,' signaling that a sale or further strategic transactions remain actively on the table.
Other KPIs
Up sequentially from $286.6M in Q3, demonstrating the Reversing trend from cash burn to cash generation. The balance sheet remains pristine with zero debt. This robust liquidity provides a strong runway for the Recordati transition and potential strategic maneuvering.
A massive 88% improvement from the $(52.5) million loss in Q4 2024. Including $4.1M in restructuring charges, the core operations were effectively at breakeven. Operating margin improved from (84%) to (13%).
Accelerating. Up 20% YoY from $2.2M, driven by higher in-market sales generated by global partners. As the Recordati partnership matures, this high-margin revenue line will be the primary indicator of international success.
Guidance
Reversing. After years of structured cash burn, management expects 2026 to be cash flow positive for the full year. This is driven by the stabilized US business and the annualized impact of the $70M cost-saving initiative.
Decelerating. The company incurred $36.2 million in FY25. With only a fraction remaining to be realized in early 2026, the cash drag from severance and transition costs will disappear, clearing the path for clean profitability.
Key Questions
Recordati Milestones
Now that the Recordati transition in Europe is largely complete, what specific volume milestones or timelines should investors watch for regarding potential sales-triggered milestone payments?
U.S. Pricing Dynamics
With the US business stabilizing sequentially in 2025, how should we model the net price trajectory in 2026 given recent PBM contract renewals?
Strategic Review Priorities
Regarding the ongoing strategic review with Barclays, has achieving positive cash flow shifted the Board's preference away from a near-term sale and toward standalone execution?